Aldeyra Therapeutics, Inc. (ALDX)
NASDAQ: ALDX · IEX Real-Time Price · USD
3.820
-0.050 (-1.29%)
Jul 19, 2024, 4:00 PM EDT - Market closed
Aldeyra Therapeutics Employees
Aldeyra Therapeutics had 10 employees as of December 31, 2023. The number of employees decreased by 5 or -33.33% compared to the previous year.
Employees
10
Change (1Y)
-5
Growth (1Y)
-33.33%
Revenue / Employee
n/a
Profits / Employee
-$3,000,895
Market Cap
226.96M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
23andMe Holding Co. | 582 |
2seventy bio | 274 |
Butterfly Network | 225 |
NeuroPace | 171 |
Molecular Partners AG | 168 |
Acrivon Therapeutics | 61 |
Design Therapeutics | 58 |
ESSA Pharma | 50 |
ALDX News
- 4 weeks ago - Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable - Business Wire
- 5 weeks ago - Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease - Business Wire
- 5 weeks ago - Aldeyra Therapeutics to Host Investor Roundtable Q&A - Business Wire
- 7 weeks ago - Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference - Business Wire
- 2 months ago - Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease - Business Wire
- 3 months ago - Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day - Business Wire
- 3 months ago - Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024 - Business Wire
- 4 months ago - Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease - Business Wire